Definium Therapeutics, Inc.
General ticker "DFTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.1B (TTM average)
Definium Therapeutics, Inc. follows the US Stock Market performance with the rate: 51.9%.
Estimated limits based on current volatility of 6.0%: low 30.49$, high 34.38$
Factors to consider:
- Current price 102.3% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.92$, 17.50$]
- 2026-12-31 to 2027-12-31 estimated range: [5.88$, 13.76$]
Financial Metrics affecting the DFTX estimates:
- Negative: with PPE of -6.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: 68.95 < Shareholder equity ratio, % of 75.51 <= 81.82
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0.46 <= 0.49
Short-term DFTX quotes
Long-term DFTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $93.87MM | $103.92MM | $166.31MM |
| Operating Income | $-93.87MM | $-103.92MM | $-166.31MM |
| Non-Operating Income | $-1.87MM | $-4.76MM | $-17.48MM |
| Interest Expense | $0.92MM | $2.28MM | $5.48MM |
| R&D Expense | $48.96MM | $65.30MM | $117.67MM |
| Income(Loss) | $-95.73MM | $-108.68MM | $-183.79MM |
| Net Income(Loss)* | $-95.73MM | $-108.68MM | $-183.79MM |
| Stockholders Equity | $78.13MM | $241.45MM | $332.33MM |
| Assets | $124.54MM | $302.15MM | $440.10MM |
| Operating Cash Flow | $-64.36MM | $-79.13MM | $-131.56MM |
| Investing Cash Flow | $0.00MM | $0.00MM | $-151.61MM |
| Financing Cash Flow | $21.85MM | $253.20MM | $267.27MM |
| Earnings Per Share** | $-2.44 | $-1.54 | $-2.06 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.